Top Featured Companies Dominating the Cardiomyocytes Landscape
- AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis
- Pfizer
- Roche
- Johnson & Johnson
- Merck & Co., Inc.
- Bayer
- Abbott Laboratories
- Bristol Myres
- Cytiva
Browse Key Market Insights with Data Illustration:
In the News
- 31st January 2024
Abbott Park, Illinois /PRNewswire/ -- The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.
- 6th December 2023
Novartis announced that Fabhalta® (iptacopan) has been approved by the U.S. Food and Drug Administration (FDA) as the first oral monotherapy for the management of adults suffering from paroxysmal nocturnal hemoglobinuria (PNH)1. A Factor B inhibitor, fabhalta functions proximally in the immune system's alternative complement pathway, offering complete regulation of the destruction of red blood cells (RBCs) both inside and outside of blood vessels (intra- and extravascular hemolysis [IVH and EVH]).
